Upregulation of cyclin‐dependent kinase 7 and matrix metalloproteinase‐14 expression contribute to metastatic properties of gastric cancer

Naseh, Ghodratolah; Mohammadifard, Mahyar; Mohammadifard, Mahtab

doi:10.1002/iub.1543

Cited by 20 publications

(33 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous studies in determining the status of HER2 IHC method is used first. Soon after, with CISH having such unique properties, this method of staining was chosen to investigate HER2 gene amplification [ 6 ] [ 13 ] [ 14 ] [ 16 ] [ 18 ] [ 19 ] [ 20 ] [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma

Atabati¹,

Raoofi²,

Amini³

et al. 2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND:In patients with breast cancer, HER2 gene expression is of a great importance in reacting to Herceptin treatment. To evaluate this event, immunohistochemistry (IHC) has been done routinely on the basis of scoring it and so the patients were divided into 4 groups. Lately, as there have been disagreements about how to treat score 2 patients, chromogenic in situ hybridization (CISH) and florescence in situ hybridization (FISH) are introduced. Since CISH method is more convenient than FISH for gene amplification study, FISH has been substituted by CISH.AIM:The current study is conducted in order to investigate whether using CISH is a better method comparison to IHC method for determines HER2 expression in patients with breast cancer in.METHODS:In this cross-sectional descriptive analytical study, information of 44 female patients with invasive ductal breast cancer were gathered from Imam Reza and Omid Hospital in Mashhad. IHC staining was done for all patients in order to determine the level of HER2 expression, and after scoring them into 4 groups of 0, +1, +2 and +3, CISH staining was carried out for all 4 groups. At the end, results from both methods were statistically evaluated using SPSS software V.22.0.RESULTS:The average age of patients was 50.2 with the standard deviation of 10.96. Using IHC method was observed that 2.6% (1 patient), 26.3% (10 patients), 65.8% (25 patients) and 5.3% (2 patients) percentage of patients had scores of 0, +1, +2 and +3. On the other hand, CISH method showed 36 patients (90%) with no amplifications and 4 (10%) with sever amplifications. In a comparative study using Fisher’s exact test (p = 0.000), we found a significant relation between IHC method and CISH method indicating that all patients showing severe amplifications in CISH method, owned scores of +2 and +3 in IHC method.CONCLUSION:According to the present study and comparing the results with similar previous studies, it can be concluded that CISH method works highly effective in determining HER2 expression level in patients with breast cancer. This method is also able to determine the status of patients with score +2 in IHC for their treatment with herceptin.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma

Atabati¹,

Raoofi²,

Amini³

et al. 2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…Two decades ago, immunohistochemical analyses on a range of tumour types indicated that CDK7 expression is elevated in tumour cells compared with their normal counterparts [67]. Since then, numerous studies have provided support for this finding [68][69][70][71][72][73]. In oestrogen receptor-positive (ER+) breast cancer, CDK7, cyclin H and MAT1 are overexpressed and are co-regulated at the mRNA level [68].…”

Section: Cdk7 Expression In Tumoursmentioning

confidence: 99%

“…Conversely, in triple-negative breast cancer (TNBC), CDK7 expression is correlated with poor prognosis [74]. In addition, associations between CDK7 and reduced survival have been observed in gastric cancer [69,70], ovarian cancer [75], oral squamous cell carcinoma (OSCC) [71], hepatocellular carcinoma [72] and glioblastoma [73]. For OSCC, animal studies have also revealed a potential role for CDK7 in disease development [71].…”

Section: Cdk7 Expression In Tumoursmentioning

confidence: 99%

CDK7 inhibitors as anticancer drugs

Sava

Fan

Coombes

et al. 2020

Cancer Metastasis Rev

137

115

View full text Add to dashboard Cite

Cyclin-dependent kinase 7 (CDK7), along with cyclin H and MAT1, forms the CDK-activating complex (CAK), which directs progression through the cell cycle via T-loop phosphorylation of cell cycle CDKs. CAK is also a component of the general transcription factor, TFIIH. CDK7-mediated phosphorylation of RNA polymerase II (Pol II) at active gene promoters permits transcription. Cell cycle dysregulation is an established hallmark of cancer, and aberrant control of transcriptional processes, through diverse mechanisms, is also common in many cancers. Furthermore, CDK7 levels are elevated in a number of cancer types and are associated with clinical outcomes, suggestive of greater dependence on CDK7 activity, compared with normal tissues. These findings identify CDK7 as a cancer therapeutic target, and several recent publications report selective CDK7 inhibitors (CDK7i) with activity against diverse cancer types. Preclinical studies have shown that CDK7i cause cell cycle arrest, apoptosis and repression of transcription, particularly of super-enhancer-associated genes in cancer, and have demonstrated their potential for overcoming resistance to cancer treatments. Moreover, combinations of CDK7i with other targeted cancer therapies, including BET inhibitors, BCL2 inhibitors and hormone therapies, have shown efficacy in model systems. Four CDK7i, ICEC0942 (CT7001), SY-1365, SY-5609 and LY3405105, have now progressed to Phase I/II clinical trials. Here we describe the work that has led to the development of selective CDK7i, the current status of the most advanced clinical candidates, and discuss their potential importance as cancer therapeutics, both as monotherapies and in combination settings. ClinicalTrials.gov Identifiers: NCT03363893; NCT03134638; NCT04247126; NCT03770494.

show abstract

“…75 articles were further removed because of non-DSC or the samples were not detected in protein expression levels or were not derived from tissue. Finally, 20 eligible articles [42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61] were included in this meta-analysis (Table 1).…”

Section: Identification Of the Eligible Studiesmentioning

confidence: 99%

Expression of MMP-14 and prognosis in digestive system carcinoma: a meta-analysis and databases validation

Duan¹,

Peng²,

Yin³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background:The Matrix metalloproteinase-14 (MMP-14) expression has been shown to be overexpressed in different cancers. However, there is no comprehensive quantitative evaluation of the MMP-14 prognostic value in digestive system carcinoma (DSC). The aim of this study is to explore the correlation between the MMP-14 expression and DSC prognosis. Methods: We conducted a meta-analysis to estimate the association strength between MMP-14 expression and prognosis. GEPIA and Kaplan Meier plotters were used to assess overall survival (OS), disease-free survival (DFS)/progression-free survival (PFS) in DSC patients and the differential expression of MMP-14 in DSC tissues and adjacent tissues. Results: A total of 20 studies including 2,519 patients with OS and 438 patients with DFS/PFS data were analyzed in evidence synthesis. Overall, the combined hazard ratio (HR) with 95% confidence interval (95% CI) was 1.98 (95%Cl: 1.77-2.22, P<0.001) for OS and 3.61 (95%Cl: 2.39-5.43, P<0.001) for DFS/PFS. For subgroup analyses, significant correlations were revealed between increased MMP-14 expression and poor OS in patients with gastric cancer (HR=2.21, 95%CI: 1.76-2.77, P<0.001), esophageal carcinoma (HR=2.01, 95%CI: 1.58-2.57, P<0.001), oral cancer (HR = 1.69, 95% CI: 1.30-2.20, P < 0.001) (HR=2.14, 95%CI 1.35-2.19, P<0.001) and hepatocarcinoma. In database verification analyses, the MMP-14 expression levels in normal tissues were significantly higher than that in DSC tissues, and significant associations were observed between high MMP-14 expression levels and poor prognosis. Conclusions:The high expression levels of MMP-14 might predict poor prognosis in DSC. Larger prospective clinical cohort studies are required to validate the prognostic role.

show abstract

Upregulation of cyclin‐dependent kinase 7 and matrix metalloproteinase‐14 expression contribute to metastatic properties of gastric cancer

Cited by 20 publications

References 38 publications

Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma

Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma

CDK7 inhibitors as anticancer drugs

Expression of MMP-14 and prognosis in digestive system carcinoma: a meta-analysis and databases validation

Contact Info

Product

Resources

About